Zoetis (ZTS) Depreciation & Amortization (CF) (2012 - 2026)
Zoetis' (ZTS) quarterly Depreciation & Amortization (CF) came in at $119.0 million in Q1 2026, little changed year-on-year from $119.0 million in Q1 2025, and down 1.65% on a QoQ basis from $121.0 million in Q4 2025.
Zoetis (ZTS) Depreciation & Amortization (CF) (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $119.0 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) changed 0.0% year-over-year to $119.0 million in Q1 2026; TTM through Mar 2026 was $487.0 million, a 0.61% decrease from a year earlier, with the FY2025 full-year figure at $487.0 million, down 2.01% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $119.0 million, down from $121.0 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for ZTS reached as high as $127.0 million in Q2 2024 and fell as low as $114.0 million in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $121.1 million across 5 years, with a median of $121.0 million in 2023.
- Across the five-year window, Depreciation & Amortization (CF) rose 7.83% in 2023 and decreased 5.56% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $119.0 million in 2022, then grew by 5.88% to $126.0 million in 2023, then retreated by 2.38% to $123.0 million in 2024, then declined by 1.63% to $121.0 million in 2025, then retreated by 1.65% to $119.0 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $119.0 million in Q1 2026, $121.0 million in Q4 2025, and $124.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 119.00 Mn |
| Mar 31, 2026 | 119.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Dec 31, 2025 | 121.00 Mn |
| Sep 30, 2025 | 124.00 Mn |
| Sep 30, 2025 | 124.00 Mn |
| Jun 30, 2025 | 123.00 Mn |
| Jun 30, 2025 | 123.00 Mn |
| Mar 31, 2025 | 119.00 Mn |
| Mar 31, 2025 | 119.00 Mn |
| Dec 31, 2024 | 123.00 Mn |
| Dec 31, 2024 | 123.00 Mn |
| Sep 30, 2024 | 121.00 Mn |
| Sep 30, 2024 | 121.00 Mn |
| Jun 30, 2024 | 127.00 Mn |
| Jun 30, 2024 | 127.00 Mn |
| Mar 31, 2024 | 126.00 Mn |
| Mar 31, 2024 | 126.00 Mn |
| Dec 31, 2023 | 126.00 Mn |
| Dec 31, 2023 | 126.00 Mn |